Jonathan  Biller net worth and biography

Jonathan Biller Biography and Net Worth

CFO & Head of Corp. Affairs of Agios Pharmaceuticals
Mr. Biller joined Agios as Chief Legal Officer in November 2019, and expanded his role to Chief Financial Officer and Head of Legal and Corporate Affairs in September 2020. He served as executive vice president, general counsel at Celgene from July 2018 to November 2019 where he was responsible for Celgene’s global legal function. He joined Celgene in 2011, serving as senior vice president, tax and treasury, responsible for Celgene’s global tax and treasury functions including the company’s capital allocation strategy and tax policy. Prior to Celgene, Mr. Biller was general counsel, chief tax officer and secretary, from 2008 to 2011 at Bunge Limited, a publicly traded agriculture and food company. Prior to Bunge, Mr. Biller held roles of increasing responsibility at Alcon, Inc. during which time it was a publicly traded company. He began his legal career at Hopkins & Sutter rising to the level of partner and was also partner at Foley & Lardner after the firms merged. Mr. Biller also serves on the Board of Junior Achievement New Jersey. He holds a B.A. degree from Brown University and a J.D. from Yale Law School.

How do I contact Jonathan Biller?

The corporate mailing address for Mr. Biller and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Jonathan Biller's contact information.

Has Jonathan Biller been buying or selling shares of Agios Pharmaceuticals?

Jonathan Biller has not been actively trading shares of Agios Pharmaceuticals in the last ninety days. Learn More on Jonathan Biller's trading history.

Who are Agios Pharmaceuticals' active insiders?

Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Agios Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.

Information on this page was last updated on 12/11/2024.

Jonathan Biller Insider Trading History at Agios Pharmaceuticals

See Full Table

Jonathan Biller Buying and Selling Activity at Agios Pharmaceuticals

This chart shows Mr. Jonathan Biller's buying and selling at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $41.16
Low: $40.50
High: $42.36

50 Day Range

MA: $50.09
Low: $38.17
High: $61.64

2 Week Range

Now: $41.16
Low: $20.96
High: $62.58

Volume

371,212 shs

Average Volume

719,470 shs

Market Capitalization

$2.35 billion

P/E Ratio

3.62

Dividend Yield

N/A

Beta

0.8